Repository logo
 

A lncRNA fine tunes the dynamics of a cell state transition involving Lin28, let-7 and de novo DNA methylation

Published version
Peer-reviewed

Change log

Authors

Smith, AG 

Abstract

Execution of pluripotency requires progression from the naïve status represented by mouse embryonic stem cells (ESCs) to a state capacitated for lineage specification. This transition is coordinated at multiple levels. Non-coding RNAs may contribute to this regulatory orchestra. We identified a rodent-specific long non-coding RNA (lncRNA) linc1281, hereafter Ephemeron (Eprn), that modulates the dynamics of exit from naïve pluripotency. Eprn deletion delays the extinction of ESC identity, an effect associated with perduring Nanog expression. In the absence of Eprn, Lin28a expression is reduced which results in persistence of let-7 microRNAs, and the up-regulation of de novo methyltransferases Dnmt3a/b is delayed. Dnmt3a/b deletion retards ES cell transition, correlating with delayed Nanog promoter methylation and phenocopying loss of Eprn or Lin28a. The connection from lncRNA to miRNA and DNA methylation facilitates the acute extinction of naïve pluripotency, a pre-requisite for rapid progression from preimplantation epiblast to gastrulation in rodents. Eprn illustrates how lncRNAs may introduce species-specific network modulations.

Description

Keywords

Lin28a/Mirlet7, de novo DNA methylation, developmental biology, long non-coding RNA, mouse, pluripotency, stem cell transition, stem cells, Animals, Cell Differentiation, DNA (Cytosine-5-)-Methyltransferases, DNA Methylation, DNA Methyltransferase 3A, Gene Deletion, Gene Expression Regulation, Mice, MicroRNAs, Mouse Embryonic Stem Cells, RNA, Long Noncoding, RNA-Binding Proteins, DNA Methyltransferase 3B

Journal Title

eLife

Conference Name

Journal ISSN

2050-084X
2050-084X

Volume Title

6

Publisher

eLife Sciences Publications Ltd
Sponsorship
The Royal Society (nf110751)
European Research Council (268569)
Medical Research Council (MC_PC_12009)
Biotechnology and Biological Sciences Research Council (BB/M004023/1)
Wellcome Trust (096125/Z/11/Z)
Wellcome Trust (091484/Z/10/Z)
Wellcome Trust (092096/Z/10/Z)
Cancer Research Uk (None)
AS is supported by Medical Research Council (G1100526/1), Biotechnology and Biological Sciences Research Council (BB/M004023/1), European Commission (HEALTH-F4-2007-200720 EUROSYSTEM), and Wellcome Trust (091484/Z/ 10/Z). LH is supported by National Cancer Institute (R01 CA139067, 1R21CA175560-01) and California Institute of Regenerative Medicine (RN2-00923-1), American Cancer Society (123339-RSG-12- 265-01-RMC), Tobacco-related Disease Research Program (21RT-0133). DLS is supported by NIGMS 42694 and NCI 5PO1CA013106-Project 3. TK is supported by programme grants from Cancer Research UK (C6/A18796) and European Research Council CRIPTON Grant (268569) and core grants from the Wellcome Trust (092096) and Cancer Research UK (C6946/A14492). The Cambridge Stem Cell Institute receives core funding from the Wellcome Trust and the Medical Research Council. MAL was a Siebel postdoctoral fellow at the University of California, Berkeley and a Sir Henry Wellcome postdoctoral fellow (096125/Z/11/Z). AS is a Medical Research Council Professor.